Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell Carcinoma
PHASE4CompletedINTERVENTIONAL
Enrollment
100
Participants
Timeline
Start Date
January 31, 2002
Study Completion Date
September 30, 2005
Conditions
Carcinoma, Basal Cell
Interventions
DRUG
Imiquimod
Trial Locations (1)
72076
Skin Cancer Program, Department of Dermatology, Liebermeisterstrasse 8, Tübingen
All Listed Sponsors
lead
University Hospital Tuebingen
OTHER
NCT00204555 - Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell Carcinoma | Biotech Hunter | Biotech Hunter